Clinical trials: Safety, Psychological
Erectile Dysfunction
Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors
This study examines the efficacy and safety of the combination treatment BAY60-4552 plus vardenafil in patients with erectile dysfunction, who do not sufficiently respond to therapy with PDE5 (Phosphodiesterase 5) inhibitors.
- Trial name
- NCT01168817
- Testing
- BAY60-4552 plus Vardenafil, Vardenafil
- Where
- 36 sites in Finland, France and 5 more
- Volunteers
- 140 people
- Sponsor
- Bayer
Obesity, Health Behavior
DEMETRA - ADVICE-002-2022
The purpose of this study is to evaluate the safety and performance of DTXO App in improving weight loss and weight-loss maintenance in obese patients exposed to an experimental non-pharmacological treatment program.
- Conditions
- Obesity, Health Behavior, Life Style, Dietary Habits
- Trial name
- NCT05394779
- Testing
- DTXO APP
- Where
- Italy
- Volunteers
- 246 people
- Sponsor
- Advice Pharma Group srl
Erectile Dysfunction
Radial Shockwave Therapy for Erectile Dysfunction
Objective: To evaluate the efficacy and safety of radial shock waves for the treatment of erectile dysfunction [ED]. Patients and methods: Randomized, double-blind clinical trial.
- Trial name
- NCT03596047
- Testing
- Radial wave therapy
- Where
- Colombia
- Volunteers
- 80 people
- Sponsor
- Boston Medical Group
Erectile Dysfunction
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00229073
- Testing
- dapoxetine
- Volunteers
- 1,116 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
The study is divided into 2 parts. The first part of the study will be double-blinded and will last for 24 weeks. During this time, participants will be randomized in a ratio of 2:1 to receive either evolocumab once monthly (QM)…
- Trial name
- NCT02833844
- Testing
- Evolocumab
- Where
- 78 sites in United States, Australia and 13 more
- Volunteers
- 467 people
- Sponsor
- Amgen
Sexual Dysfunctions, Psychological, Sexual Arousal Disorder
An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder
The purpose of this study is to evaluate the safety and toleration of oral sildenafil administered as required by women with Female Sexual Arousal Disorder (FSAD) who successfully complete one of the following Pfizer-sponsored…
- Trial name
- NCT00746967
- Testing
- sildenafil
- Where
- 82 sites in United States
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Life Stress, Fatigue
Multicentre, Double-blind Study Versus Placebo on Impact and Safety of Extramel® 140 IU on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception if Present, and the Impact on the Quality of Life
Objectives of this Multicentre, double-blind study versus placebo were to evaluate impact and safety of the daily administration of Extramel® 140 IU SOD for 12 weeks on perceived stress, physical and intellectual fatigue, pain…
- Conditions
- Life Stress, Fatigue, Pain, Quality of Life
- Trial name
- Ex Stress II (NCT01767922)
- Testing
- Extramel 10 mg - 140 UI SOD
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Robertet SA
Vaginal Atrophy, Sexual Dysfunction
Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause
This multi-center clinical trial will evaluate the safety and long-term efficacy of hybrid fractional 2940 nm and 1470 nm lasers for treatment of symptoms of Genitourinary Syndrome of Menopause.
- Conditions
- Vaginal Atrophy, Sexual Dysfunction, Dyspareunia, Vaginal Dryness
- Trial name
- NCT03178825
- Testing
- Hybrid Fractional Laser
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sciton
Well-Being, Psychological
EXOMIND (BTL-699-2) for Improvement of Mental Well-being
The goal of this clinical trial is to evaluate if the treatment with EXOMIND (BTL-699-2) device is able to improve mental well-being in adults above the age of 22 years.
- Trial name
- NCT06899646
- Testing
- Treatment with BTL-699-2
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Erectile Dysfunction
A Thorough EKG Safety Study of TA-1790 (Avanafil)
This study is to assess whether treatment with a therapeutic (100 mg) or supratherapeutic (800 mg) dose of avanafil has the potential to cause QT/QTc prolongation in healthy volunteers.
- Trial name
- NCT00769041
- Testing
- moxifloxacin, avanafil, sugar pill
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Erectile Dysfunction, Premature Ejaculation
Efficacy and Safety of Toronto Association in the Treatment of Erectile Dysfunction and Premature Ejaculation
The purpose of this study is to evaluate the efficacy and safety of Toronto association in the treatment of both sexual dysfunction: erectile dysfunction and premature ejaculation.
- Trial name
- NCT05052879
- Testing
- Toronto association, Tadalafil
- Volunteers
- 232 people
- Sponsor
- EMS
Vulvo Vaginal Atrophy (VVA)
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
Study Objectives: Primary: To assess the safety, tolerability, and systemic pharmacokinetics (PK) of AZU-101 Secondary: To evaluate efficacy of daily vaginal doses of AZU-101 in postmenopausal women on vaginal epithelium
- Trial name
- NCT06197568
- Testing
- Lasofoxifene Tartrate
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Azure Biotech Inc.
Endometriosis
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have…
- Trial name
- EDELWEISS 5 (NCT04372121)
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Endometriosis
A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement…
- Trial name
- NCT03986944
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 112 sites in United States, Canada and 1 more
- Volunteers
- 85 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Erectile Dysfunction
Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)
This study is being conducted to compare the safety and efficacy of 2 doses of avanafil to placebo in diabetic men with mild to severe erectile dysfunction.
- Trial name
- REVIVE-D (NCT00809471)
- Testing
- avanafil
- Where
- 39 sites in United States
- Volunteers
- 390 people
- Sponsor
- VIVUS LLC
Hypoactive Sexual Desire Disorder
Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems
A double-blind, randomized, placebo-controlled, dose-finding study to investigate the safety and efficacy of Lybridos in the domestic setting in healthy female subjects with hypoactive sexual desire disorder and maladaptive…
- Trial name
- NCT01743235
- Testing
- Testosterone, Buspirone hydrochloride
- Where
- 12 sites in United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Emotional Brain NY Inc.
Erectile Dysfunction
Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patients With Diabetes.
Sixty diabetes men with erectile dysfunction from mild to severe who agree to participate is going to have medical care approximately for 16 weeks.
- Trial name
- NCT01180283
- Testing
- lodenafil carbonate
- Where
- 3 sites in Brazil
- Sponsor
- Cristália Produtos Químicos Farmacêuticos Ltda.
Healthy Male Volunteers
A Phase I Study to Investigate KH-001 in Healthy Males
This was a Phase I, first-in-human study of KH-001 besylate in healthy male participants, conducted to investigate the safety, tolerability and pharmacokinetics (PK) of the study drug.
- Trial name
- NCT07868237
- Testing
- KH-001 besylate
- Where
- United Kingdom
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Kadence Bio
Premature Ejaculation
FTIH Study With GSK958108
This study is the first administration of GSK958108 to man. The study will evaluate the safety, tolerability and pharmacokinetics of single ascending doses of GSK958108 and evaluate the effect of food on GSK958108 pharmacokinetics
- Trial name
- NCT00664365
- Testing
- GSK958108
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Erectile Dysfunction
Safety and Efficacy of YHD1023 in Erectile Dysfunction
The objective of this study is to assess the safety and efficacy of oral YHD1023 5g or 10g on erectile dysfunction to investigate the optimal recommended dosage.
- Trial name
- NCT01423370
- Testing
- YHD1023, Cialis
- Where
- South Korea
- Volunteers
- 104 people
- Sponsor
- Yuhan Corporation